Generate Biomedicines (NASDAQ:GENB) versus Monte Rosa Therapeutics (NASDAQ:GLUE) Financial Survey

Generate Biomedicines (NASDAQ:GENB – Get Free Report) and Monte Rosa Therapeutics (NASDAQ:GLUE – Get Free Report) are both small-cap healthcare companies, but which is the better stock? We will compare the two businesses based on the strength of their dividends, institutional ownership, risk, valuation, earnings, profitability and analyst recommendations.

Profitability

This table compares Generate Biomedicines and Monte Rosa Therapeutics’ net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
Generate Biomedicines -1,289.97% -151.21% -54.73%
Monte Rosa Therapeutics -186.24% -30.14% -20.35%

Earnings and Valuation

This table compares Generate Biomedicines and Monte Rosa Therapeutics”s top-line revenue, earnings per share (EPS) and valuation.

Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
Generate Biomedicines $31.89 million 48.86 -$203.15 million ($1.59) -7.59
Monte Rosa Therapeutics $123.67 million 6.47 -$38.63 million ($1.40) -6.69

Monte Rosa Therapeutics has higher revenue and earnings than Generate Biomedicines. Generate Biomedicines is trading at a lower price-to-earnings ratio than Monte Rosa Therapeutics, indicating that it is currently the more affordable of the two stocks.

Analyst Recommendations

This is a summary of recent ratings and target prices for Generate Biomedicines and Monte Rosa Therapeutics, as reported by MarketBeat.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Generate Biomedicines 1 1 6 0 2.62
Monte Rosa Therapeutics 1 2 8 1 2.75

Generate Biomedicines presently has a consensus target price of $26.40, suggesting a potential upside of 118.72%. Monte Rosa Therapeutics has a consensus target price of $26.44, suggesting a potential upside of 182.22%. Given Monte Rosa Therapeutics’ stronger consensus rating and higher possible upside, analysts clearly believe Monte Rosa Therapeutics is more favorable than Generate Biomedicines.

Institutional & Insider Ownership

80.0% of Monte Rosa Therapeutics shares are held by institutional investors. 6.4% of Monte Rosa Therapeutics shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.

Summary

Monte Rosa Therapeutics beats Generate Biomedicines on 12 of the 13 factors compared between the two stocks.

About Generate Biomedicines

(Get Free Report)

Generate Biomedicines is a biotechnology company that uses generative artificial intelligence and experimental biology to design and develop medicines. Founded in 2018 by Flagship Pioneering, the company is based in Somerville, Massachusetts. Its platform is designed to create new proteins with potential therapeutic applications, including antibodies and other biologic medicines. Generate is advancing a drug-development pipeline across areas such as immunology and oncology; one of its candidates, GB-0895, is being developed for asthma.

About Monte Rosa Therapeutics

(Get Free Report)

Monte Rosa Therapeutics is a clinical-stage biotechnology company developing molecular glue degraders, medicines designed to direct disease-associated proteins for disposal by the cell. Its discovery platform combines computational and experimental methods to identify and develop these potential treatments. The company’s research has included programs for cancer and immune-mediated diseases. Its pipeline includes MRT-6160, a VAV1 degrader being developed for autoimmune and inflammatory conditions, and MRT-8102, an investigational degrader targeting the NLRP3 inflammasome pathway.

Receive News & Ratings for Generate Biomedicines Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Generate Biomedicines and related companies with MarketBeat.com's FREE daily email newsletter.